Bruce Mitlak

Chief Medical Officer

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Bruce Mitlak is the Chief Medical Officer at Radius Health in the United States. His research focuses on bone health, particularly in postmenopausal women, with recent articles addressing topics such as the effectiveness and safety of abaloparatide in treating osteoporosis. He has contributed to studies on bone mineral density, fracture risk reduction, and the impact of anabolic therapies.

Articles (10)

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Collaborators (3)

David Dempster

Professor

Columbia University

UNITED STATES

View details

Felicia Cosman

Professor of Medicine

Columbia University Vagelos College of Physicians and Surgeons

UNITED STATES

View details

Dwight Towler

Professor and J.D. and Maggie E. Wilson Distinguished Chair in Biomedical Research; Louis V. Avioli Professorship in Mineral Metabolism; Associate Dean, Resident Research

University of Texas Southwestern Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Bruce Mitlak

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Healing sequelae following tooth extraction and dental implant placement in an aged, ovariectomy model

Response rates for lumbar spine, total hip, and femoral neck bone mineral density in men treated with abaloparatide: results from the ATOM study

Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend

Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A US administrative claims database study

Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis.

Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density

Forearm bone mineral density and fracture incidence in postmenopausal women with osteoporosis: results from the ACTIVExtend phase 3 trial

Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial.

Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis

Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project

Collaborators (3)

David Dempster

Felicia Cosman

Dwight Towler

Make your next move.